Ocuphire Pharma Investor Updates
P
12
Demographics (PP Population)
Treatment And Placebo Arms Were Balanced In This Phase 2 Clinical Trial
Age (years): Median
(Range)
Sex: Male n (%)
Female n (%)
Race: White n (%)
African American n (%)
Asian n (%)
Other* n (%)
Dark Iris Color: n (%)
Placebo
Alone
N=43
52
(42-62)
15 (35%)
28 (65%)
37 (86%)
4 (9%)
2 (5%)
0 (0%)
18 (42%)
25 (58%)
Nyxol
Alone
N=30
54
(41-60)
7 (23%)
23 (77%)
26 (87%)
0 (0%)
0 (0%)
1 (3%)
12 (40%)
18 (60%)
Light Iris Color: n (%)
* includes American Indian or Alaska Native; Native Hawaiian or Other Pacific Islander
Source: VEGA-1 TLR Table 14.1.2.2 Demographics and Baseline Characteristics (PP Population)
LDP
Alone
N=31
52
(44-64)
13 (42%)
18 (58%)
28 (90%)
1 (3%)
6 (6%)
1 (3%)
12 (39%)
19 (61%)
Nyxol+LDP
N=43
53
(43-63)
5 (12%)
38 (88%)
40 (93%)
0 (0%)
6 (6%)
0 (0%)
18 (42%)
25.1 (58%)
Total
N=147
53
(41-64)
40 (27%)
107 (73%)
131 (89%)
3 (2%)
11 (5%)
2 (1%)
60 (41%)
87 (59%)
Ocuphire
PHARMAView entire presentation